Johan Luthman, Executive Vice President, R&D, Lundbeck  

“New Frontiers in Precision Medicine – The Neurology Example”

Johan Luthman began his pharmaceutical career at AstraZeneca in 1991 and went on to hold senior neuroscience, immunology, and R&D leadership roles at Serono, Merck Serono, GeNeuro, Merck, Eisai, and Lundbeck, where he became Executive Vice President of R&D in 2019. Luthman holds a Doctor of Dental Sciences degree, a PhD in Neurobiology and Histology, and an Associate Professorship from Karolinska Institute, and also serves on the Board of Directors of Brain+. 

Hear from Novartis across the conference programme to gain comprehensive insights into their biomarker strategy:

• CELINE PALLAUD, Vice President, Head Precision Medicine
• JACEK LUKAWY, Innovation Program Director, Translational Medicine
• MICHAEL REBHAN, Associate Director
• CARSTEN KRANTZ, Associate Director

Join our day one track dedicated to Companion Diagnostics & Regulations, with insights from the following companies on regulatory expectations for AI-derived biomarkers, computational pathology & CDx development 

•    AbbVie
•    Merck 
•    Vertex 
•    AstraZeneca 
•    Roche 
•    ZHAW

The AI & Data Zone will serve as the central hub for AI-driven biomarker discovery, computational pathology and next generation multi-omics technologies, bringing together innovators across AI platforms, cloud infrastructure, automation, bioinformatics, digital biology, academic hubs, and strategic pharma tech partners. This interactive space will feature poster presentations, live demos, and short tech talks, alongside an AI Networking Lounge and a coffee cart to foster meaningful connections & collaborations. 

Gain insights from the people at the forefront of the AI revolution in pathology across European pharma:  

• AstraZeneca
• Roche
• Merck Sharp & Dohme
• Merck KgaA
• Gilead
• UCB